27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Therapies targeting amyloid, such as monoclonal antibodies like Lecanemab, Aducanumab, and Donanemab, have garnered FDA approval but remain controversial due to limited clinical benefits and significant side effects against Alzheimer. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Detection of the early phases of cognitive dysfunction is critical for identifying individuals at risk of neurodegeneration before irreversible damage occurs. 3 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
The association declines monotonically as control over ascertainment improves. 5 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dysregulated insulin signaling in brain has been linked to cognitive impairment and dementia. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
The global burden of dementia is heavily concentrated in low- and middle-income countries (LMICs), yet biological diagnosis of Alzheimer’s Disease (AD) relies on positron emission tomography (PET) and cerebrospinal fluid (CSF) analysis that are operationally inaccessible in these regions. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Of 352 records identified, five studies involving 245 participants were included. 5 key findings →
Participants: 245 Evidence: low
Full summary, score breakdown and related studies → Original source
Psychosis is a neuropsychiatric feature found across neurodegenerative conditions including Alzheimer’s disease (AD) and Parkinson’s disease (PD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) affects women more than men, with risk increasing during and after the menopausal transition. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This structural configuration shields the scaffold from calpain-mediated cleavage, reconfiguring FLNA into an active motility engine driving invasive lamellipodia but stalls proteolytic processing and forces an absolute loss of the nuclear FLNA-90 tumor-suppressor brake, unleashing uninhibited c-Myc oncogenic transcription. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Electroencephalography (EEG) records cortical activity with high temporal resolution without radiation and at low cost, which makes it a practical signal for automated screening of neurological disorders. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
For more than 150 years, since the idea that mental illness is rooted in the brain first emerged in the mid-1800s, psychiatry has searched for a reliable biological system to anchor its understanding of mental illness. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We then integrated healthy retinal expression, AD retinal proteomics, and PD aqueous-humor proteomics with the brain-concordance results. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Chronic metabolic diseases, including Type 2 Diabetes, hypertension, non-alcoholic fatty liver disease (NAFLD), prostate enlargement, musculoskeletal joint friction, cardiac arrhythmias, neurodegenerative waste accumulation (Alzheimer's), and elevated intraocular hydraulic pressure (glaucoma), are frequently treated as distinct, unavoidable consequences of chronological aging. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The short-wavelength content of available light declines steadily through the afternoon, well before nightfall, while the long-wavelength component remains nearly constant. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) pathology is increasingly recognized to manifest in the retina, offering a non-invasive window for early biomarker discovery. 2 key findings →
Design: longitudinal study Participants: 40 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Artificial intelligence (AI) is now a credible translational research platform across the Alzheimer’s disease (AD) pathway, but its clinical value is often difficult to judge from performance metrics alone. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Neurodegenerative research has long hypothesized that aggregated proteins such as amyloid‑β (Aβ), tau, and α‑synuclein (αSyn) are intrinsically toxic and are directly associated with the etiologies of Alzheimer’s disease (AD) and Parkinson’s disease (PD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The occurrence of amyloid-related imaging abnormalities (ARIA), found in clinical trials for Aβ-immunotherapy, has been related to the antibody’s effector function on glial activation by the Fc portion of the antibody. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Mitochondrial dysfunction, oxidative stress, neuroinflammation, and impaired protein homeostasis form interconnected pathological networks in acute central nervous system injury and chronic neurodegenerative disease. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have moved rapidly from metabolic medicine into neurology, but the evidence to mid-2026 refuses to resolve into a single narrative of neuroprotection. 5 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
EVOKE and EVOKE+ trials showed no population-level slowing of early symptomatic Alzheimer’s disease (AD) with semaglutide, motivating an assessment of whether clinical-note phenotyping over decades of routine care could identify distinct AD trajectories. 3 key findings →
Participants: 2,169 Evidence: low
Full summary, score breakdown and related studies → Original source
Scrapie, a prion disease, is usually considered a protein-only infection. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Insomnia disorder affects approximately 10–20% of adults and is usually chronic. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Of total 8,321 participants, 24.88% (2,070) developed cognitive impairment during a 10-year follow-up. 5 key findings →
Design: longitudinal study Participants: 8,321 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) is characterised by progressive accumulation of misfolded proteins and failure of cellular clearance pathways, particularly the autophagy–lysosomal system. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →